Приказ основних података о документу

dc.creatorPantelić, Ivana
dc.creatorLukić, Milica
dc.creatorGojgić-Cvijović, Gordana
dc.creatorJakovljević, Dragica
dc.creatorNikolić, Ines
dc.creatorLunter, Dominique Jasmin
dc.creatorDaniels, Rolf
dc.creatorSavić, Snežana
dc.date.accessioned2020-02-11T11:41:27Z
dc.date.available2020-02-11T11:41:27Z
dc.date.issued2020
dc.identifier.issn0928-0987
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/3500
dc.description.abstractOngoing demand in sustainable and biocompatible drug dosage forms is reflected in the search for novel pharmaceutical excipients with equal properties. A group of microbial exopolysaccharides offers a variety of biopolymers with many alleged uses and effects. This study aims to assess applicative properties of levan obtained from Bacillus licheniformis NS032, focusing on its potential co-stabilizing and drug release-controlling functions in pertaining emulsion systems. Despite its high molecular weight and partial existence in globular nanometric structures (180-190 nm), levan was successfully incorporated into both tested colloidal systems: those stabilized with synthetic/anionic or natural-origin/non-ionic emulsifiers. In the tested levan concentrations range (0.2-3.0% w/w) the monitored flow and thermal parameters failed to show linear concentration dependence, which prompted us to revisit certain colloidal fundamentals of this biopolymer. Being a part of the external phase of the investigated emulsion systems, levan contributed to formation of a matrix-like environment, offering additional stabilization of the microstructure and rheology modifying properties (hysteresis loop elevation as high as 4167±98 to 20792±3166 Pa•s−1), especially in case of the samples where lamellar liquid crystalline formation occurred. Apart from its good water solubility and considerable conformational flexibility, the investigated homofructan easily saturated the external phase of the samples stabilized with a conventional anionic emulsifier, leading to similar properties of 0.2% and 3.0% levan-containing samples. After closer consideration of thermal and release behavior, this was considered as a favorable property for a novel excipient, offering tailored formulation characteristics even with lower levan concentrations, consequently not compromising the potential cost of the final drug dosage form.en
dc.publisherElsevier
dc.relationinfo:eu-repo/grantAgreement/MESTD/Technological Development (TD or TR)/34031/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/43004/RS//
dc.rightsrestrictedAccess
dc.sourceEuropean Journal of Pharmaceutical Sciences
dc.subjectArticle
dc.subjectBacillus licheniformis
dc.subjectCo-stabilizer
dc.subjectDiclofenac diethylamine
dc.subjectEmulsion systems
dc.subjectExopolysaccharides
dc.subjectPharmaceutical Excipient
dc.titleBacillus licheniformis levan as a functional biopolymer in topical drug dosage forms: From basic colloidal considerations to actual pharmaceutical applicationen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractНиколић, Инес; Даниелс, Ролф; Савић, Снежана; Пантелић, Ивана; Лукић, Милица; Гојгић-Цвијовић, Гордана; Јаковљевић, Драгица; Лунтер, Доминиqуе Јасмин;
dc.citation.volume142
dc.citation.rankM21
dc.identifier.wos000505188900003
dc.identifier.doi10.1016/j.ejps.2019.105109
dc.identifier.scopus2-s2.0-85075300448
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу